and low-and high-grade anal intraepithelial neoplasms (LGAIN and HGAIN, respectively). Since multiple teams are involved in the identification and treatment of anal dysplasia, a standardized nomenclature is essential. Otherwise, there will be significant variability in the caregiver's response as well as ongoing barriers to effective communication between specialties.
The nomenclature for dysplasia has evolved over the years. Originally, pathologist graded anal dysplasia into three main categories: mild, moderate, and severe. With the institution of the Bethesda classification for cervical intraepithelial neoplasia (CIN) by the National Cancer Institute, pathologic similarities and similar association with HPV were identified between CIN and AIN, which was subsequently classified into a three-tier system: AINs 1, 2, and 3 based on degrees of dysplasia.
11 Unfortunately, there was poor interobserver reliability for AIN II among pathologists which made the confusion even worse. 12 Other earlier terms including Bowen's disease and carcinoma in situ are also not currently preferred. Some groups refer to AIN 1 and AIN 2 as low-grade intraepithelial neoplasia (LGAIN) and AIN 3 as high-grade intraepithelial neoplasia, (HGAIN); this nomenclature is based on histology rather than cytology, but is generally considered an outdated terminology.
The most standard and up-to-date nomenclature involves a two-tier system where AIN 1 was identified as LSIL and AIN 2 and AIN 3 were identified as HSIL. 13 This was initially based on cytology rather than histology, but has now been extended to include histologic findings. This classification has been adopted by the College of American Pathologists, as well as the American Joint committee on Cancer (AJCC) and the American Society for Colposcopy and Cervical Pathology. 14, 15 Further subclassification into AIN 1, 2, and 3 is still acceptable, but should not replace LSIL and HSIL. Knowledge of the terms used to describe dysplasia at the institutional level facilitates discussion among providers within the multidisciplinary team (MTD) and avoids confusion between pathologists and the other clinicians involved in the care of patients with dysplasia. For the purpose of this chapter, when discussing anal dysplasia as a generic term and disease process, we will refer to it as AIN. When discussing the dysplastic process detected on cytology, in terms of low grade or high grade, we will refer to it as LSIL and HSIL, respectively. This is the most common nomenclature used by the National Comprehensive Cancer Network (NCCN), AJCC, the International Anal Neoplasia Society (IANS), as well as discussion panels by the American Society of Colon and Rectal Surgeons (ASCRS).
Role of the Pathologist
The main role of the pathologist is to accurately diagnose and grade AIN and anal cancer. The pathologist must have a significant attention to detail, as AIN is typically asymptomatic, and often arises in specimens sent to the pathology laboratory without specific concern for dysplasia. This includes hemorrhoidectomy, fissurectomy, and other anorectal procedure. 16, 17 AIN is identified on cytological screening. It is also sometimes identified on colonoscopy, where polypoid lesions can be mistaken by the endoscopes for adenomatous polyps. 18 An astute pathologist can often be the first member of the treatment team to identify dysplasia, and thus activate the process that eventually leads to the patient being evaluated by a specialist. Beyond the diagnosis of AIN, the pathologist must also be an excellent communicator with the other members of the treatment team as management strategies start with a pathologic diagnosis, and the subtle microscopic differences in the degrees of anal dysplasia and atypia can result in major treatment shifts. The pathologist often possesses the greatest understanding of the proper terminology, and can thus be an excellent resource to the treatment team when developing a subsequent plan.
Many different disciplines including gastroenterology and colorectal surgery have emphasized the importance of clear communication between pathologists and clinicians in optimizing the care of patients. 19, 20 Anal pathology can be confusing with significant overlap between disease, but the evaluation and management of the individual patient with suspected AIN is significantly aided by clear communication between the pathologist and the treating clinician.
21
Screening and the Role of the Primary Care Physician
The exponential growth of managed care has led to a more prominent role of PCPs in the American health care system, who practice under two fundamental principles: comprehensiveness and continuity. 22 PCPs should thus be involved in the comprehensive care of patients with AIN/anal cancer, and those who are at high risk, by obtaining adequate history and physical, screening when needed, administering vaccination when appropriate, and providing referrals when necessary. PCPs can often be responsible for coordinating care between the different specialists caring for AIN patients, and can provide long-term follow-up and management of patients who are not in need of immediate specialist expertise. As mentioned previously, AIN is typically asymptomatic and often detected incidentally during treatments for unrelated problems such as hemorrhoids or anal warts, unlike anal cancer that presents with progressive symptoms of bleeding, pain, and a palpable mass.
23 AIN can thus go unnoticed for years before it presents as anal cancer. In fact, historical studies reported a delay of more than 2 years in diagnosis of anal cancer, a disease that has good prognosis when detected early, but has poor survival when it is missed or when patients present late (10% 5-year survival for metastatic disease).
24,25
This is why early detection and screening efforts have been advocated by some societies, such as the Infectious Disease Society in America (IDSA), which issued guidelines recommending screening for anal dysplasia in high-risk patients including MSM, women with a history of receptive anal intercourse or abnormal cervical Pap test results, and all HIV-infected persons with genital warts.
26
PCPs are ideal forefront players in the identification of these high-risk patients and their subsequent inclusion in the screening process. PCPs are usually the first health care providers to encounter patients with AIN, especially when they remain asymptomatic. PCPs should be comfortable obtaining a disease-specific history, performing an adequate anal physical exam with evaluation of advanced disease such as inguinal nodes, as well as screening for AIN when applicable. PCPs must always maintain an appropriate level of suspicion for AIN and anal cancer when patients present with vague anorectal complaints. One of the most important roles of the primary care provider is knowing when it is appropriate to refer a patient to a colorectal surgeon for evaluation.
When it comes to screening, anal Papanicolaou (pap) smear has been proposed as a test for AIN, modeled after the screening for cervical dysplasia to which AIN draws similarities. 27 The clinician samples the anal transition zone by taking a moistened swab to obtain a smear of the area. 28 This should be done before digital rectal exam is performed, as the lubricant used in digital examination can confound and interfere with the interpretation of the pap smear specimen. 
43,44
HIV infection also contributes to the development of AIN and anal cancer. HIV-positive individuals have been found to have a higher prevalence of HPV coinfection, higher prevalence of the high-risk HPV types (such as HPV 16 subtype), and higher prevalence of multiple concomitant HPV genotypes compared with HIV-negative individuals. 45, 46 Additionally, HIV-infected individuals have a higher prevalence of LSIL, as well as an increased rate of progression of LSIL into HSIL than HIV-negative individuals, particularly in MSM.
45,47
Due to the intricate relationship between AIN and its virulent etiology, HPV, along with the compounding effect of HIV, the ID specialist becomes a point person in the care of AIN patients. Up to 70% of HIV-positive patients harbor anal dysplasia, despite the use of antiretroviral therapy. 48 This leaves ample opportunities for detection of AIN in the hands of ID specialist who at times are the first and only health care workers providing care for HIV-positive patients and their partners. Additionally, social and behavioral factors influence the incidence and degree of anal dysplasia within the HIV population. For instance, a study showed that HIV-positive patients who are not exposed to anoreceptive intercourse, such as heterosexual injection drug users, have a 46% prevalence of anal HPV infection, whereas LSIL was found in 16% of patients and HSIL in 18% of patients. 49 On the other hand, a study of HIVpositive MSM showed that 95% harbored anal HPV, 81% had AIN, and 52% had HSIL. 50 The ID specialist should then have a good understanding of socio-behavioral factors that may be associated with an HIV diagnosis, and further stratify HIV and HPV patients into higher or lower risk categories for screening, treatment, and follow-up on anal dysplasia. The work of the ID specialist on screening high-risk populations (e.g., HIV-positive MSM), and in the prevention, treatment, and long-term management of HIV and/or HPV in these and other individuals, has important effects on AIN disease burden and therefore serves as an integral role in the task force against AIN.
High-Resolution Anoscopy, Treatment Strategies, and the Role of the Colorectal Surgeon
The colorectal surgeon is often the "captain of the ship" for patients with AIN, being involved in all aspects of the diagnosis, treatment, and subsequent surveillance. The surgeon must have a global understanding of the disease process from its infectious, immunologic, and primary care standpoint. More often, patients with AIN are referred to the colorectal surgeon from other clinics or specialties for advanced level of care of the anorectal disease. Knowledge and comfort with anorectal anatomy, as well as the availability of resources for treatment or surveillance of AIN, makes the colorectal surgeon indispensable to the treatment and care of AIN patients. Once AIN has been diagnosed, addressing the lesion is paramount against the progression into anal cancer.
10,51 However, treatment strategies and algorithms differ among colorectal surgeons and a definite consensus has not yet been reached. On the more conservative end of the spectrum is the "watchful waiting" approach which involves observation alone with close clinical follow-up every 4 to 6 months, an approach advocated by some in select cases of AIN.
52 Supporters of this watchful waiting approach base the strategy on overall low rates of disease progression and malignant potential of AIN, especially LSIL, and the increased morbidity associated with excision and repeated focal destruction. A more hands-on "expectant management" strategy that includes cytology, high-resolution anoscopy (HRA), targeted biopsies, and directed therapy has reported clearance of AIN in up to 80%, with less than 5% progression to high-grade lesions or invasive cancer on 10-year follow-up.
53,54
HRA is one technique for screening and surveilling AIN that often requires colorectal surgeons' expertise as well as their technical resources. It is described in detail in another article of this volume. The documented sensitivity and specificity of HRA vary in the literature with values as low as 60% to values as high as 100%, as it is an operatordependent procedure with an associated learning curve, and it is more accurate in diagnosing populations at high risk such as HIV-positive men. [55] [56] [57] The efficiency and costeffectiveness of HRA for screening has been demonstrated to be superior to other screening modalities 58 and HRA has been considered standard of care for any patient with prior abnormal anal pap test by some institutions such as the New York State Department of Health AIDS Institute. 59 In communities where there are no clinicians available to perform HRA, patients with abnormal anal cytology on pap smear should be referred to a surgeon for evaluation. Interestingly, a study on 424 patients with AIN showed that there is no difference in progression into whether patients were followed with HRA surveillance versus expectant management, as long as they were compliant with frequent follow-up.
9
Some colorectal surgeons advocate the addition of topical adjuncts to the surveillance strategy, such as topical 5% imiquimod cream which has lesion clearance in more than 80% of patients but has side effects such as burning and erosions that lead to discontinuation of therapy, 60,61 topical 5% 5-FU cream which has similar clinical response but more tolerable side effects such as hypopigmentation, 62, 63 or photosensitizing agents such as 5-aminolevulinic acid creams followed by treatment with a specific nano-wavelength laser as part of photodynamic therapy, an evolving field with data from small case reports that require further investigation and validation to evaluate outcomes.
64-66
The most invasive side of the spectrum for management of AIN involves operative approaches such as wide local excision (WLE) which depends on frozen sections and establishing negative margins, but can leave anal defects of average size of 17.4 cm 2,67 along with complications of anal stenosis or incontinence. 68 In general, such an approach is overly invasive for an exclusively mucosal or epidermal process. Conventional or HRA-guided lesion destruction is a more conservative operative approach to AIN, in which lesions are destroyed with electrocautery, infrared coagulation, or cryotherapy. Since destruction is confined to the anoderm and rectal mucosa without entry into the deeper layers, dysplastic lesions can be effectively eradicated without creating the large field defect seen in WLE.
54,69,70
Operative management of AIN is very effective in eradicating lesions and preventing progression into anal cancer, but recurrence rates for AIN are very high, ranging from 9 to 90% depending on patient risk factors such as HIV positivity, MSM, and immunocompromised status. 67, [71] [72] [73] This could be attributed to the persistence of HPV in residual anal tissue and its continuous effect on inducing dysplasia. In view of this high risk of recurrence, it is imperative that colorectal surgeons ensure continuous surveillance of patients even after treatment of their AIN lesions; however, surveillance strategies after the treatment of AIN are nonuniform. In general, the colorectal surgeon will see the patient at regular intervals for a detailed anorectal exam using HRA or conventional anoscopy.
For patients who remain compliant with surveillance recommendations, progression from AIN to cancer is very low. The decision of how conservative or aggressive treatment of AIN lesions should rests on the colorectal surgeon and their experience, skill, and comfort level, while also factoring patient-related variables such as medical complexity, highrisk individuals for recurrence/progression (HIV-and HPVpositive patients, MSM), as well as patient compliance to therapy regimen.
Because AIN patients present to the colorectal surgeon at all points of disease evolution, a comprehensive understanding of the different available treatment modalities is paramount. The colorectal surgeon also plays a crucial role in explaining the disease process to patients, who are often quite intimidated by the realization that they harbor an increased lifelong risk of anal cancer.
Multidisciplinary Approach to AIN and Anal Cancer
Although colorectal surgeons are experts in anorectal anatomy, and have the ability to deal with both early and late manifestations of anal dysplastic disease, the care of AIN should not, and cannot, rest entirely on their shoulders (►Table 1). Screening for AIN for instance is a responsibility that can be shared by providers from different specialties that care for established AIN patient or those at risk. A survey of 290 colorectal surgeons who encounter AIN in their practice showed that less than 50% of surgeons performed screening for AIN, for reasons such as lack of time, or not wanting screening to take over their practice, and 20% stated that they would rather refer screening elsewhere.
74
HRA is one such area of screening that could see improvements, as there is likely a paucity of expertly trained providers experienced in this technology to make screening easily accessible. 75 Over the past several years, the American Society for Colposcopy and Cervical Pathology has sought to promote the use of this screening modality, by sponsoring training courses and workshops in HRA. Gynecologists or other providers, such as nurse practitioners and physician assistants, who often perform cervical colposcopy, can easily learn the techniques necessary to perform the procedure in the anus. In addition, clinicians experienced in HRA should be able to train other interested health care providers outside of a formal course. This makes screening more accessible in areas where colorectal surgeons are not easily available, and it eases the burden of screening from being restricted to colorectal surgeons only performing the procedure. The care of complex diseases like anal intraepithelial and subsequent anal cancer is multidisciplinary. MDTs were originally introduced to ensure that all patients receive timely treatment and care from appropriately skilled professionals, to guarantee continuity of care and to provide patients with adequate information and support. The teams also monitor adherence to clinical guidelines and can promote the effective use of resources.
76
In anal cancer, a MDT approach includes input and coordination between the various specialists managing the disease. The United Kingdom, for instance, has been a pioneer in applying the MDT model for the management of anal cancer: the country's anal cancer care is distributed over regional cancer networks, and each network or pair of networks is responsible for creating a MDT team for anal cancer made up of colorectal surgeons, oncologists, radiologists, pathologists, dedicated MDT coordinator, advanced nurse specialists, and data manager. 77 The Despite a paucity of data to support the approach of MDT in managing precursor lesions such as AIN, a team's approach to this disease is ideal, in view of the disease complexity and the interplay of the different specialties involved. MDT becomes particularly pertinent in the setting of recurrences, questionable lesions, progression to cancer, as well as sharing expertise in areas of high incidence such as San Francisco and New York City.
Conclusion
Anal dysplasia is a complex disease that is increasing in prevalence. Caring for anal dysplasia requires an extensive infrastructure, including PCPs to screen at-risk populations, pathologists to identify and properly label the different grades of the disease, ID specialists to understand the virology component of the disease and to treat a significant portion of people at risk such as HIV-positive patient and MSM, experienced high-resolution anoscopists to detect and survey lesions, and colorectal surgeons to treat AIN lesions inside or outside the operating room. A MTD who utilizes the expertize of each of the disciplines involved can improve the care of AIN patients.
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